Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morpholine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morpholine SCHEMBL3822890 | 1.00 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL14957611 | 0.91 | MEN1 (0.65) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL11524539 | 0.91 | MEN1 (0.65) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL4018377 | 0.91 | MEN1 (0.65) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL9998486 | 0.88 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL9998476 | 0.88 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL28322795 | 0.87 | — | — | |
| Morpholine SCHEMBL21145050 | 0.87 | MEN1 (0.52) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL5707215 | 0.86 | MEN1 (0.58) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL219044 | 0.86 | KMT2A (0.58) | MEN1KMT2AKDM4EGAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110437069-A | The method for continuously synthesizing of 2- fluorine diester malonate class compound | ASYMCHEM LIFE SCIENCE TIANJIN CO LTD | 2019-11-12 | — | — | CN | claimed |
| CN-101595098-B | 1,2,4-triazole derivatives as sigma receptor inhibitors | ESTEVE LABOR DR | 2012-07-18 | — | — | CN | claimed |
| CN-101595098-A | As 1,2 of sigma receptor inhibitors, the 4-triazole derivative | ESTEVE LABOR DR (ES) | 2009-12-02 | — | — | CN | claimed |
| EP-2097394-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-09 | — | — | EP | claimed |
| WO-2008055932-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-05-15 | — | — | WO | claimed |
| CN-119768395-A | Processes and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives | 库里亚西班牙公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20200179254-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2020-06-11 | — | — | US | disclosed |
| CN-110437069-A | The method for continuously synthesizing of 2- fluorine diester malonate class compound | ASYMCHEM LIFE SCIENCE TIANJIN CO LTD | 2019-11-12 | — | — | CN | disclosed |
| US-20190240129-A1 | CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2019-08-08 | — | — | US | disclosed |
| EP-3518878-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | Henkel AG & Co. KGaA (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-20190216703-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2019-07-18 | — | — | US | disclosed |
| US-20190216714-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2019-07-18 | — | — | US | disclosed |
| CN-102036985-A | 4(-3- (-2- (phenyl) morpholino) -2-oxopyrrolidin-1-yl) -N- (thiazol-2-yl) benzenesulfonamide derivatives and related compounds as modulators of ion channels for the treatment of pain | VERTEX PHARMA | 2011-04-27 | — | — | CN | disclosed |
| CN-101595098-A | As 1,2 of sigma receptor inhibitors, the 4-triazole derivative | ESTEVE LABOR DR (ES) | 2009-12-02 | — | — | CN | disclosed |
| EP-2097394-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-09 | — | — | EP | disclosed |
| CN-101395152-A | Sigma receptor compounds | ESTEVE LABOR DR (ES) | 2009-03-25 | — | — | CN | disclosed |
| WO-2008055932-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-05-15 | — | — | WO | disclosed |
| CN-101014570-A | Piperidine derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2007-08-08 | — | — | CN | disclosed |
| CN-1021323-C | PROCESS FOR PREPARING ANTIDEPRESSANTS | MERRELL DOW PHARMA (US) | 1993-06-23 | — | — | CN | disclosed |
| CN-1033043-A | The method for making of new antidepressive | MERRELL DOW PHARMA (US) | 1989-05-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240129-A1 | CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, CUTA, S100A10 | MEN1 3369/4885KMT2A 242/4885KDM4E 461/4885 |
| US-20190216703-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, SRRM2, IK | MEN1 4505/4885KMT2A 912/4885KDM4E 1699/4885 |
| US-20190216714-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, CD44, PCNA | MEN1 2001/4885KMT2A 97/4885KDM4E 251/4885 |
| US-20200179254-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, CUTA, DSG1 | MEN1 3038/4885KMT2A 59/4885KDM4E 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.